Immix Biopharma - Encouraging progress on multiple fronts
Immix Biopharma has announced interim response rate data from its newly formed subsidiary, Nexcella, concerning the BCMA-targeting cell therapy...
453 Views
Immix Biopharma - Potential upside with expansion into CAR-T
Immix Biopharma has announced the in-licensing of NXC-201, a novel chimeric antigen receptor T-cell (CAR-T) therapy, which has shown high response...
752 Views
Immix Biopharma - IMX-110 clinical expansion on the horizon
Immix Biopharma’s 9M22 financial results were consistent with our full year estimates. The company reported operating losses of US$4.4m, up from...
345 Views
Immix Biopharma - Fresh faces with a unique tissue-targeting therapy
Immix Biopharma is a clinical-stage biopharmaceutical company focused on the development of its SMARxT tissue-specific platform producing...
769 Views